Doron Therapeutics is a clinical-stage biotechnology company that has developed a Phase 3 ready, intra-articular biologic drug derived from placental tissue. The lead product, MOTYS™, consistently delivers a host of beneficial growth factors with potent anti-inflammatory, tissue-protective and regenerative capabilities pivotal to the progressive and degenerative disease of osteoarthritis.
New York
545 West 25th Street, 20th Floor New York, NY, USA 10001
Singapore
79 Science Park Drive, Level 06 Unit 01/08, CINTECH IV, Science Park 1 Singapore 118264
New York
545 West 25th Street, 20th Floor New York, NY, USA 10001
Singapore
79 Science Park Drive, Level 06 Unit 01/08, CINTECH IV, Science Park 1 Singapore 118264
Total raised: $11M
Investors 1
| Date | Name | Website |
| 10.07.2026 | SPRIM Glob... | sprim.net |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.11.2024 | Series A | $11M | - |
Mentions in press and media 4
| Date | Title | Description |
| 20.05.2025 | Doron Therapeutics Announces Positive End-of-Phase 2 and Initial RMAT Meeting With FDA for MOTYS (PTP-001) in the Treatment of Knee Osteoarthritis | - |
| 27.11.2024 | Doron Therapeutics Raises $11M in Series A Funding | Doron Therapeutics, a Chapel Hill, NC-based clinical-stage biotech company focusing on degenerative musculoskeletal conditions, raised $11M in Series A funding. The round was led by SPRIM Global Investments (SGI). The company intends to use... |
| 25.11.2024 | Doron Therapeutics Raises $11M Series A to Progress Biologic Regenerative Osteoarthritis Drug into Phase 3 Clinical Studies | CHAPEL HILL, NC / ACCESSWIRE / November 25, 2024 / Doron Therapeutics, a clinical-stage biotech company focusing on degenerative musculoskeletal conditions, today announced it has successfully raised an aggregate $11 million as an initial S... |
| - | Doron Therapeutics | “Doron Therapeutics - Mobility is a Gift” |